Compare CRON & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRON | CMPX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 926.7M |
| IPO Year | 2015 | 2020 |
| Metric | CRON | CMPX |
|---|---|---|
| Price | $2.64 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.43 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $117,615,000.00 | $850,000.00 |
| Revenue This Year | $18.81 | N/A |
| Revenue Next Year | $34.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.82 | N/A |
| 52 Week Low | $1.60 | $1.33 |
| 52 Week High | $3.43 | $6.88 |
| Indicator | CRON | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 43.18 |
| Support Level | $2.44 | $4.78 |
| Resistance Level | $2.77 | $5.86 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 21.70 | 6.54 |
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.